ZA201202793B - Humanized antibodies against human il-22ra - Google Patents

Humanized antibodies against human il-22ra

Info

Publication number
ZA201202793B
ZA201202793B ZA2012/02793A ZA201202793A ZA201202793B ZA 201202793 B ZA201202793 B ZA 201202793B ZA 2012/02793 A ZA2012/02793 A ZA 2012/02793A ZA 201202793 A ZA201202793 A ZA 201202793A ZA 201202793 B ZA201202793 B ZA 201202793B
Authority
ZA
South Africa
Prior art keywords
antibodies against
humanized antibodies
against human
human
humanized
Prior art date
Application number
ZA2012/02793A
Other languages
English (en)
Inventor
Roland Beckmann
Caroline Johnson-Leger
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41565648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201202793(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of ZA201202793B publication Critical patent/ZA201202793B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA2012/02793A 2009-11-19 2012-04-17 Humanized antibodies against human il-22ra ZA201202793B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09176525 2009-11-19
US26299809P 2009-11-20 2009-11-20
PCT/EP2010/067332 WO2011061119A1 (en) 2009-11-19 2010-11-12 Humanized antibodies against human il-22ra

Publications (1)

Publication Number Publication Date
ZA201202793B true ZA201202793B (en) 2013-06-26

Family

ID=41565648

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/02793A ZA201202793B (en) 2009-11-19 2012-04-17 Humanized antibodies against human il-22ra

Country Status (20)

Country Link
US (1) US8545844B2 (enExample)
EP (1) EP2512511B1 (enExample)
JP (1) JP5818804B2 (enExample)
KR (1) KR20120098783A (enExample)
CN (1) CN102665759B (enExample)
AU (1) AU2010321047B2 (enExample)
BR (1) BR112012012003A2 (enExample)
CA (1) CA2778864C (enExample)
EA (1) EA021356B1 (enExample)
EC (1) ECSP12011980A (enExample)
ES (1) ES2531996T3 (enExample)
IL (1) IL219740A0 (enExample)
IN (1) IN2012DN03362A (enExample)
MX (1) MX2012005791A (enExample)
NZ (1) NZ599438A (enExample)
PE (1) PE20121560A1 (enExample)
PH (1) PH12012500924A1 (enExample)
UA (1) UA105405C2 (enExample)
WO (1) WO2011061119A1 (enExample)
ZA (1) ZA201202793B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007004770A (es) * 2004-10-22 2007-11-22 Zymogenetics Inc Anticuerpos anti-il-22ra y moleculas y metodos para usarlos en inflamacion.
HUE039849T2 (hu) 2011-03-16 2019-02-28 Argenx Bvba CD70 elleni ellenanyagok
CN107318267B (zh) 2013-08-12 2021-08-17 豪夫迈·罗氏有限公司 用于治疗补体相关的病症的组合物和方法
PE20161440A1 (es) * 2014-05-01 2017-01-26 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
ES2966133T3 (es) * 2016-03-18 2024-04-18 Staidson Beijing Biopharmaceuticals Co Ltd Proteína de fusión que comprende el factor de crecimiento nervioso y método de preparación y uso de la misma
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
EP3630182A4 (en) * 2017-05-24 2021-02-24 Development Center for Biotechnology HUMANIZED ANTIBODIES TO GLOBO H AND THEIR USE IN CANCER TREATMENT
KR102611853B1 (ko) 2017-06-30 2023-12-08 자임워크스 비씨 인코포레이티드 안정화된 키메라 fabs
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
WO2023232789A1 (en) * 2022-06-03 2023-12-07 Leo Pharma A/S Liquid formulation of il-22r antibody
WO2024184333A1 (en) 2023-03-08 2024-09-12 Leo Pharma A/S Il-22r antibody for use in treating atopic dermatitis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
MX2007004770A (es) * 2004-10-22 2007-11-22 Zymogenetics Inc Anticuerpos anti-il-22ra y moleculas y metodos para usarlos en inflamacion.
KR20070114324A (ko) * 2005-03-25 2007-11-30 글리카트 바이오테크놀로지 아게 Ｍｃｓｐ 에 향하며 증가된 ｆｃ 수용체 결합 친화도 및효과기 작용을 갖는 항원 결합 분자
CA2631961A1 (en) * 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling relating to antibodies that bind to il-22

Also Published As

Publication number Publication date
BR112012012003A2 (pt) 2016-11-29
ES2531996T3 (es) 2015-03-23
EP2512511B1 (en) 2015-01-07
EA021356B1 (ru) 2015-05-29
CA2778864A1 (en) 2011-05-26
ECSP12011980A (es) 2012-07-31
CN102665759B (zh) 2015-09-30
MX2012005791A (es) 2012-07-03
IN2012DN03362A (enExample) 2015-10-23
CA2778864C (en) 2017-06-27
AU2010321047A1 (en) 2012-05-24
WO2011061119A1 (en) 2011-05-26
PE20121560A1 (es) 2012-12-05
AU2010321047B2 (en) 2016-06-09
NZ599438A (en) 2013-12-20
PH12012500924A1 (en) 2012-11-26
EA201290360A1 (ru) 2012-11-30
CN102665759A (zh) 2012-09-12
JP2013511267A (ja) 2013-04-04
US20120230990A1 (en) 2012-09-13
KR20120098783A (ko) 2012-09-05
UA105405C2 (ru) 2014-05-12
US8545844B2 (en) 2013-10-01
IL219740A0 (en) 2012-07-31
JP5818804B2 (ja) 2015-11-18
EP2512511A1 (en) 2012-10-24

Similar Documents

Publication Publication Date Title
IL217919A0 (en) Humanized anti-cdcp1 antibodies
ZA201202793B (en) Humanized antibodies against human il-22ra
IL207217A0 (en) Humanized anti-c5ar antibodies
IL220404A (en) Antiseptic antibodies
PL2949666T3 (pl) Ludzkie przeciwciała przeciwko alfa-synukleinie
ZA201107529B (en) Humanized axl antibodies
IL218724A0 (en) Endoglin antibodies
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
GB0909906D0 (en) Antibodies
ZA201207484B (en) Humanized anti-egfl7 antibodies and methods using same
ZA201106480B (en) Humanized anti-cd19 antibody formulations
IL215314A0 (en) Humanized antibodies against light and uses thereof
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
ZA201202227B (en) Monoclonal antibodies
IL208979A0 (en) Humanized antibodies against human interferon-alpha
GB0920324D0 (en) Antibodies
GB0905972D0 (en) Antibodies against IL-17BR
IL212795A0 (en) Fully human antibodies against n-cadherin
EP2650367A4 (en) HUMAN MONOCLONAL ANTIBODY
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
GB0902916D0 (en) Antibody therapy
EP2484694A4 (en) MONOCLONAL ANTIBODY AGAINST HUMAN H1G1 POLYPEPTIDE
HRP20190159T1 (hr) Antitijela humanog anti-alfa-sinukleina
IL226635B (en) Human anti-sod1 antibodies